MX2018004503A - Receptores de antigeno quimerico anti-cd30. - Google Patents

Receptores de antigeno quimerico anti-cd30.

Info

Publication number
MX2018004503A
MX2018004503A MX2018004503A MX2018004503A MX2018004503A MX 2018004503 A MX2018004503 A MX 2018004503A MX 2018004503 A MX2018004503 A MX 2018004503A MX 2018004503 A MX2018004503 A MX 2018004503A MX 2018004503 A MX2018004503 A MX 2018004503A
Authority
MX
Mexico
Prior art keywords
chimeric antigen
antigen receptors
disclosed
cars
condition
Prior art date
Application number
MX2018004503A
Other languages
English (en)
Inventor
N Kochenderfer James
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of MX2018004503A publication Critical patent/MX2018004503A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Abstract

Se describen receptores de antígeno quiméricos (CARs) que se unen específicamente a y reconocen inmunológicamente CD30. También se describen ácidos nucleicos relacionados, vectores de expresión recombinantes, células anfitrionas, poblaciones de células y composiciones farmacéuticas relacionadas con los CARs. También se describen métodos de tratamiento y prevención de la condición de un mamífero, donde la condición es cáncer.
MX2018004503A 2015-10-15 2016-10-10 Receptores de antigeno quimerico anti-cd30. MX2018004503A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562241896P 2015-10-15 2015-10-15
PCT/US2016/056262 WO2017066122A1 (en) 2015-10-15 2016-10-10 Anti-cd30 chimeric antigen receptors

Publications (1)

Publication Number Publication Date
MX2018004503A true MX2018004503A (es) 2019-04-15

Family

ID=57178532

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004503A MX2018004503A (es) 2015-10-15 2016-10-10 Receptores de antigeno quimerico anti-cd30.

Country Status (11)

Country Link
US (1) US10815301B2 (es)
EP (1) EP3362476B1 (es)
JP (1) JP2018531014A (es)
KR (1) KR20180057723A (es)
CN (1) CN108137703A (es)
AU (1) AU2016338747B2 (es)
BR (1) BR112018006995A2 (es)
CA (1) CA3002000A1 (es)
IL (1) IL258527A (es)
MX (1) MX2018004503A (es)
WO (1) WO2017066122A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI728309B (zh) * 2018-02-01 2021-05-21 大陸商南京馴鹿醫療技術有限公司 一種結合ｂｃｍａ的嵌合抗原受體（ｃａｒ）及其應用
IT201800003464A1 (it) * 2018-03-13 2019-09-13 Ospedale Pediatrico Bambino Gesu Cellule T CAR-CD30 per il trattamento di tumori CD30+
US11951131B2 (en) 2018-07-03 2024-04-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-SLAMF7 chimeric antigen receptors
CN112955172A (zh) * 2018-09-17 2021-06-11 美国卫生和人力服务部 靶向cd19和cd20的双顺反子嵌合抗原受体及其用途
EP3856778A1 (en) * 2018-09-24 2021-08-04 The Medical College of Wisconsin, Inc. System and method for the development of cd30 bispecific antibodies for immunotherapy of cd30+ malignancies
US11584799B2 (en) * 2018-09-24 2023-02-21 Medical College Of Wisconsin, Inc. Anti-CD30 antibodies and methods for treating CD30+ cancer
JPWO2020085480A1 (ja) * 2018-10-26 2021-09-16 国立大学法人信州大学 高効率な遺伝子改変細胞の作製方法
WO2021019706A1 (ja) * 2019-07-31 2021-02-04 国立大学法人信州大学 Ｃａｒ発現免疫細胞を含む細胞集団の製造方法
CN110628823B (zh) * 2019-10-21 2022-12-27 江苏省肿瘤医院 一种cd30 car慢病毒表达载体及其制备方法和应用
CN110559430B (zh) * 2019-10-21 2023-07-11 江苏省肿瘤医院 一种抗淋巴瘤的car-t药物及其应用
CN113527507A (zh) * 2020-04-16 2021-10-22 上海赛比曼生物科技有限公司 靶向cd22的嵌合抗原受体及其制法和应用
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
WO2022140388A1 (en) 2020-12-21 2022-06-30 Allogene Therapeutics, Inc. Protease-activating cd45-gate car
EP4271798A1 (en) 2020-12-30 2023-11-08 CRISPR Therapeutics AG Compositions and methods for differentiating stem cells into nk cells
IL303853A (en) 2021-01-29 2023-08-01 Allogene Therapeutics Inc Knockdown or knockout of one or more TAP2, NLRC5, B2m, TRAC, RFX5, RFXAP, and RFXANK to reduce T cell recognition of allogeneic cell products
KR20230148203A (ko) 2021-03-01 2023-10-24 난트바이오 인코포레이티드 항-cd30 단일클론성 항체 및 키메라성 항원 수용체
KR20220124005A (ko) 2021-03-02 2022-09-13 주식회사 이뮤노로지컬디자이닝랩 Cd30을 발현하는 세포에 독성을 나타내는 재조합 단백질 및 이를 유효성분으로 포함하는 암의 치료용 약학적 조성물
KR20230012129A (ko) 2021-07-14 2023-01-26 주식회사 이뮤노로지컬디자이닝랩 Cd30에 특이적으로 결합하는 키메릭 항원 수용체 및 이의 용도
WO2023205148A1 (en) 2022-04-19 2023-10-26 Intellia Therapeutics, Inc. Chimeric antigen receptor compositions and uses
WO2024026445A1 (en) 2022-07-29 2024-02-01 Allogene Therapeutics Inc. Engineered cells with reduced gene expression to mitigate immune cell recognition

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003043583A2 (en) 2001-11-20 2003-05-30 Seattle Genetics, Inc. Treatment of immunological disorders using anti-cd30 antibodies
BR0306808A (pt) * 2002-01-09 2005-08-30 Medarex Inc Anticorpos monoclonais humanos contra cd30
DK1545204T3 (en) 2002-09-06 2016-11-14 The Government Of The Us Secretary Dept Of Health And Human Services Immunotherapy with in vitro selected antigen-specific lymphocytes following non-myeloablative lymphodepletive chemotherapy
CA2625998C (en) 2005-10-06 2015-12-01 Xencor, Inc. Optimized anti-cd30 antibodies
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
WO2011041093A1 (en) * 2009-10-01 2011-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
WO2012129201A1 (en) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
WO2014055771A1 (en) * 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
EP3995512A1 (en) * 2013-08-26 2022-05-11 Hinrich Abken Anti cd30 chimeric antigen receptor and its use
CN105859890A (zh) * 2015-01-19 2016-08-17 西比曼生物科技（上海）有限公司 嵌合抗原受体及其基因和重组表达载体、工程化cd30靶向性的nkt细胞及其应用
WO2016134284A1 (en) * 2015-02-19 2016-08-25 University Of Florida Research Foundation, Inc. Chimeric antigen receptors and uses thereof

Also Published As

Publication number Publication date
KR20180057723A (ko) 2018-05-30
AU2016338747A1 (en) 2018-04-26
CN108137703A (zh) 2018-06-08
BR112018006995A2 (pt) 2018-10-30
US20190062426A1 (en) 2019-02-28
EP3362476A1 (en) 2018-08-22
AU2016338747B2 (en) 2023-05-18
CA3002000A1 (en) 2017-04-20
IL258527A (en) 2018-05-31
JP2018531014A (ja) 2018-10-25
WO2017066122A1 (en) 2017-04-20
US10815301B2 (en) 2020-10-27
EP3362476B1 (en) 2020-05-27

Similar Documents

Publication Publication Date Title
MX2018004503A (es) Receptores de antigeno quimerico anti-cd30.
AU2018291128A1 (en) Anti-B-cell maturation antigen chimeric antigen receptors with human domains
MX2023000818A (es) Anticuerpos anti-antigeno 4 del linfocito t citotoxico (ctla-4) y metodos para uso de los mismos.
MX2023007045A (es) Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) y metodos de uso de los mismos.
MX2020009472A (es) Receptores de antigenos quimericos anti-cd33 y sus usos.
MX2022001222A (es) Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y metodos para usarlos.
PH12019500709A1 (en) Anti-lag-3 antibodies and methods of use thereof
PH12019500193A1 (en) Chimeric antigen receptors targeting bcma and methods of use thereof
MX2017014908A (es) Proteinas de union triespecificas y metodos de uso.
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
MX2018002315A (es) Anticuerpos anti muerte programada 1 (pd 1) y metodos de uso de los mismos.
WO2016014565A3 (en) Treatment of cancer using humanized anti-bcma chimeric antigen receptor
NZ738008A (en) Tigit-binding agents and uses thereof
MX2020010530A (es) Anticuerpos humanizados contra cd269 (bcma).
MX2017004691A (es) Bloqueo de cd73.
MX2017001013A (es) Tratamiento de cáncer usando un receptor quimérico de antígeno cll-1.
WO2015142675A8 (en) Treatment of cancer using chimeric antigen receptor
MX2019012223A (es) Anticuerpos anti-cd137 y metodos de uso de los mismos.
MX2017001008A (es) Tratamiento de cancer utilizando un receptor quimerico de antigeno cd33.
NZ711946A (en) Newcastle disease viruses and uses thereof
MX2016012124A (es) Anticuerpos contra glicopeptidos inmunogenicos, composicion que los comprende y usos de estos.
MX2017003211A (es) Anticuerpos anti-met y composiciones.
PH12015501932A1 (en) Anti-cd52 antibodies
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use